Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Earl W. Brien, M.D. (57) joined our board of directors on December 2, 2016. ... The following table provides information concerning the current membership of our board committees: Earl W, Brien, M.D. - Audit Committee, Compensation Committee, Nomination and Governance Committee, Strategy Committee. ... Director Compensation Table shows total compensation of $154,270 for 2016. |
| 2017-08-29 | Name of Beneficial Owner Named Executive Officers and Directors Earl W. Brien, M.D. 421,484 Includes 360,000 shares subject to options or warrants. |
| 2018-07-05 | Dr. Earl W. Brien, M.D. (58) joined our board of directors on December 2, 2016. Dr. Brien currently serves as Chairman of the Strategy Committee of the CytRx Board of Directors. The following table provides information concerning the current membership of our board committees: Earl W, Brien, M.D. Audit Committee, Compensation Committee, Nomination and Governance Committee, Strategy Committee Chairman. The following table sets forth the compensation paid to our non-employee directors for 2017: Earl W. Brien, M.D., Director Fees Earned or Paid in Cash $97,450, Option Awards $106,400, Total $203,850. |
| 2019-06-26 | Dr. Earl W. Brien, M.D. (59) joined our board of directors on December 2, 2016. The following table sets forth the compensation paid to our non-employee directors for 2018: Earl Brien, M.D., Director Fees Earned or Paid in Cash ($) 99,800 Total ($) 99,800. The following table provides information concerning the current membership of our board committees: Earl W, Brien, M.D. Audit Committee, Compensation Committee, Nomination and Governance Committee. |
| 2020-06-12 | Dr. Earl W. Brien, M.D. (60) joined our board of directors on December 2, 2016. Our board of directors believes that Dr. Brien is highly qualified to serve as a member of the board because of his wide-ranging experience with sarcoma patients in particular, and his expertise in medical research and other matters related to the operation of a biotechnology company. |
Data sourced from SEC filings. Last updated: 2025-12-07